A Study to Evaluate the Safety and Effect of the Experimental Drugs ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 in Subjects With Chronic Hepatitis C

NCT01674725 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

187

Enrollment

INDUSTRY

Sponsor class

Conditions

Chronic Hepatitis C Infection

Interventions

DRUG: ABT-450/r/ABT-267, ABT-333
DRUG: Ribavirin

Sponsor

AbbVie (prior sponsor, Abbott)